Prulacabtagene leucel (prula-cel, ADI-001)

About Adicet Bio

Adicet Bio is developing first-in-class, allogeneic gamma delta T cell therapies designed to be safer, more readily available, and more effective in solid tumors and autoimmune diseases than current autologous CAR-T options. Its lead candidate, prula-cel (anti-CD20), is in Phase 1 development for B-cell mediated autoimmune diseases, with initial data showing a promising safety profile. The company's strategy hinges on validating its proprietary platform in autoimmune indications to derisk and fund expansion into the larger oncology market, leveraging the innate tissue-homing properties of its cell products.

Therapeutic Areas